The world’s first coronavirus disease 2019 human challenge trial using the D614G strain of severe acute respiratory syndrome 2 (SARS-CoV-2) is underway in the United Kingdom. The Wellcome Trust is funding challenge stock preparation of the Beta and Delta variant for a follow-up human challenge trial, and researchers at hVIVO are considering conducting these trials. However, little has been written thus far about the ethical justifiability of human challenge trials with SARS-CoV-2 variants of concern. We explore 2 specific characteristics of some variants that may initially be thought to make such trials unethical and conclude that SARS-CoV-2 variant challenge trials can remain ethical.

中文翻译：

---

使用新出现的严重急性呼吸系统综合症 2 变体进行人类挑战试验的伦理

世界上第一个使用严重急性呼吸系统综合症 2 （SARS-CoV-2）的 D614G 毒株（SARS-CoV-2）的冠状病毒疾病 2019 人类挑战试验正在英国进行。Wellcome Trust 正在资助 Beta 和 Delta 变体的挑战库存准备，用于后续的人体挑战试验，hVIVO 的研究人员正在考虑进行这些试验。然而，到目前为止，关于对 SARS-CoV-2 变体进行人体挑战试验的伦理合理性的报道很少。我们探索了一些最初可能被认为使此类试验不道德的变体的 2 个特定特征，并得出结论，SARS-CoV-2 变体挑战试验可以保持道德。